Senti Biosciences Inc
NASDAQ:SNTI
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
S
|
Senti Biosciences Inc
NASDAQ:SNTI
|
23.7m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
383.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
201.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.6B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Senti Biosciences Inc
Glance View
Senti Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California. The company went IPO on 2021-05-26. Senti Biosciences Inc., formerly Dynamics Special Purpose Corp., is a pre-clinical biotechnology company. The firm is developing cell and gene therapies engineered with its gene circuit platform technologies to cure diseases. Its advanced gene-circuit product candidates are directed at allogeneic CAR-NK cells for oncology. Its preclinical stage product candidates include SENTI-202, SENTI-301 and SENTI-401. The company is developing its SENTI-202 product candidate as a Logic Gated (OR + NOT) allogeneic CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML), cells while sparing the healthy bone marrow. Its SENTI-301 product candidate is a multi-Armed allogeneic CAR-NK cell therapy that it is developing for the treatment of hepatocellular carcinoma (HCC). Its SENTI-401 product candidate is a Logic-Gated allogeneic CAR-NK cell therapy that it is developing to target and eliminate colorectal cancer (CRC) cells. Gene circuit platform is its technology platform.
